Obesity Drug Market Faces Uncertainty as GLP-1 Prices Drop.

February 3rd,

Article: The global obesity drug market faces a period of uncertainty as prices for GLP-1 treatments from Novo Nordisk and Eli Lilly decline sharply in the United States. Once projected to reach $150 billion b